Prabhudas Lilladher Maintains Positive Outlook on Fortis Healthcare and HUL
Prabhudas Lilladher's reports on Fortis Healthcare and HUL highlight positive growth prospects. Fortis Healthcare is expected to maintain its operating trajectory despite a Delhi High Court-ordered forensic audit, with margin improvements driven by cost rationalization and expansions. HUL aims for volume-led revenue growth through premiumization, innovation, and market expansion, projecting a CAGR of 9% in sales by FY28. Both companies show favorable outlooks, with Fortis Healthcare rated 'Buy' and HUL retaining an 'Accumulate' rating with respective target prices of Rs 1,050 and Rs 2,320.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (67/100). Lens Score 27/100.
Outlets measured: moneycontrol, moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (62–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 7 Sept, 04:56 am. Other outlets followed.